Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Immunoglobulin G · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive SC administrations of IgG into the abdominal region starting with Treatment B, followed by Treatment A. |
| Sequence 2 | EXPERIMENTAL | Participants will receive SC administrations of IgG into the abdominal region starting with Treatment A, followed by Treatment C. |
| Sequence 3 | EXPERIMENTAL | Participants will receive SC administrations of IgG into the abdominal region starting with Treatment D, followed by Treatment C. |
| Sequence 4 | EXPERIMENTAL | Participants will receive SC administrations of IgG into the abdominal region starting with Treatment B, followed by Treatment D. |
| Name | Type | Description |
|---|---|---|
| Immunoglobulin G | DRUG | Participants will receive SC administrations of IgG |
Inclusion Criteria: * Body mass index (BMI) 18 to 36 kilograms per meter square (kg/m\^2), inclusive * For females of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during IgG administration and for 28 days after completio...
Immunoglobulin G is being studied for use in healthy participants. It is an investigational small molecule being developed by Roche Holding AG. The drug is currently in Phase 1 clinical development, meaning it has not been approved for any use and is still being tested for safety and tolerability.
Immunoglobulin G does not have a specific molecular target or target class identified in its development program. It is being studied as a small molecule in healthy participants to assess its tolerability and safety when administered subcutaneously under varying injection conditions.
Immunoglobulin G is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy participants.
Immunoglobulin G is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
Immunoglobulin G has one completed Phase 1 clinical trial, identified as NCT07025577. This study assessed the tolerability and safety of subcutaneously administered Immunoglobulin G with varying injection conditions in 82 healthy participants in the United States.
Immunoglobulin G is commonly referred to as IgG. In clinical trials, the drug is studied under the name Immunoglobulin G (IgG), and the completed Phase 1 trial NCT07025577 evaluated its subcutaneous administration in healthy participants.